Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research report report published on Monday. The firm issued a sell rating on the stock.

Senseonics Stock Up 4.0 %

Shares of NYSE SENS opened at $0.41 on Monday. Senseonics has a 12 month low of $0.37 and a 12 month high of $0.75. The firm has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.49. The company has a current ratio of 3.96, a quick ratio of 3.70 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $220.65 million, a PE ratio of -2.96 and a beta of 0.82.

Senseonics (NYSE:SENS) last posted its earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Senseonics had a negative return on equity of 225.98% and a negative net margin of 335.15%. Equities analysts expect that Senseonics will post -0.12 earnings per share for the current year.

Institutional Investors Weigh In On Senseonics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. RPO LLC bought a new position in Senseonics in the fourth quarter worth about $37,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in shares of Senseonics during the 1st quarter worth approximately $91,000. Vanguard Group Inc. raised its position in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.